In a filing, Catalyst Pharmaceuticals Inc revealed its Chief Compliance/Legal Officer Elsbernd Brian unloaded Company’s shares for reported $0.61 million on Sep 08 ’25. In the deal valued at $20.30 per share,30,000 shares were sold. As a result of this transaction, Elsbernd Brian now holds 271,039 shares worth roughly $5.44 million.
Then, Elsbernd Brian bought 30,000 shares, generating $609,035 in total proceeds.
Before that, Elsbernd Brian sold 30,000 shares. Catalyst Pharmaceuticals Inc shares valued at $585,600 were divested by the Chief Compliance/Legal Officer at a price of $19.52 per share. As a result of the transaction, Elsbernd Brian now holds 188,564 shares, worth roughly $3.78 million.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Tuesday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock jump 1.57% to $20.07. Over the last five days, the stock has gained 0.35%. Catalyst Pharmaceuticals Inc shares have fallen nearly -1.08% since the year began. Nevertheless, the stocks have fallen -3.83% over the past one year.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on 2025-08-29, dropping by -1.3 million shares to a total of 7.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 9.23 million shares. There was a decline of -16.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
